Fortress Biotech, Inc. (FBIO) Analysts See $-0.57 EPS

March 14, 2018 - By Hazel Jackson

 Fortress Biotech, Inc. (FBIO) Analysts See $ 0.57 EPS

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock increased 6.41% or $0.32 during the last trading session, reaching $5.31. About 492,420 shares traded or 216.55% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since March 14, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 3 analysts covering Fortress Biotech (NASDAQ:FBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 8 analyst reports since July 11, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Wednesday, September 27 with “Buy”. As per Tuesday, January 2, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 11. H.C. Wainwright maintained the shares of FBIO in report on Tuesday, December 12 with “Buy” rating. H.C. Wainwright maintained Fortress Biotech, Inc. (NASDAQ:FBIO) on Tuesday, December 5 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 10 report.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $268.99 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: which released: “Mustang Bio to Present at the 255th American Chemical Society National Meeting …” on March 12, 2018. Also published the news titled: “Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research …” on February 26, 2018.‘s news article titled: “Fortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference” with publication date: March 13, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.